Treating Cognitive Impairment in Patients with Schizophrenia


A recent drug trial yields encouraging results.

Schizophrenia can be accompanied by significant cognitive impairments. In this Mental Health Minute, Dr Margolin discusses the results of a Phase 1b clinical trial of a drug meant to treat these issues.

The drug in question, Cerevance's investigational compound CVN058, significantly improved biomarkers of cognitive impairments in patients suffering from schizophrenia. Dr Margolin discusses the structure of the drug trial, details the science behind the drug itself, and previews the next steps of his research.

Dr Margolin is senior vice-president, clinical and translational medicine at Cerevance, Inc.

Related Videos
nicotine use
brain schizophrenia
exciting, brain
“What we’re striving to do is conquer the unmet needs that are still here with treating ADHD, especially from a medication standpoint.”
Work takes up one-third of a patient’s life—it is important that we pay attention to it.
© 2024 MJH Life Sciences

All rights reserved.